/

DMRA

Damora Therapeutics, Inc.Open

20.12−0.13 −0.67%USD

NasdaqCM · as of Oct 13, 10:17 ET · 15m delay

Open

20.09

Prev close

20.26

Day range

19.8220.28

52-week range

4.9538.33

Volume

16.87K0.03×

Mkt cap

1.24B

P/E ttm

—

Fwd P/E

-9.26

EPS ttm

-0.2500

Div yield

0.00%

Earnings

—

From 52w high

−47.50%

Price Chart

Yahoo Finance · delayed

DMRAOct 13, 2026O 20.09H 20.28L 19.82C 20.12−0.13 (−0.67%)Vol 16.87K

SMA 5026.18
SMA 20025.85

1Y change +58.93% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

DMRA Damora Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +2.92%
1 month: −28.40%
3 months: −35.08%
6 months: −24.73%
Year to date: −12.56%
1 year: +57.80%

Valuation & ownership

Market cap: 1.24B
Enterprise value: 839.93M
P/E (ttm): —
Forward P/E: -9.26
PEG ratio: —
Price / book: 3.22
Price / sales (ttm): —
EV / EBITDA: -8.72
EPS (ttm): -0.2500
EPS (forward): -2.17
Beta (5y monthly): 1.44
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 61.74M
Float: 40.89M
Short % of float: 8.95%
Short ratio (days): 6.09
Held by insiders: 8.43%
Held by institutions: 106.03%
Avg volume (3m): 532.79K
50-day average: 26.35
200-day average: 25.90
52-week change: +57.80%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 35.5
vs 50-day SMA: −23.14%
vs 200-day SMA: −22.17%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 7.62%
Realised vol (20d, ann.): 54.1%
From 52-week high: −47.50%
From 52-week low: +306.46%

ANR

Analyst Consensus

9 analysts

Consensus

Strong buy

1.10 on a 1 (strong buy) – 5 (sell) scale

Mean target

46.89

+133.05% implied

Low 40.00Median 45.00High 60.00

Recommendation trend

Now10 / 0 / 0
1m ago10 / 0 / 0

DES

About Damora Therapeutics, Inc.

Yahoo Finance profile

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 7
Headquarters: Waltham, MA, United States
Website: damoratx.com
Officers: Mr. Garrett Winslow Esq. Senior VP, General Counsel & Corporate Secretary
Ms. Jennifer A. Jarrett M.B.A. CEO, President & Director
Mr. Ulf J. Nilsson Ph.D. Co-Founder
Dr. Hakon Leffler M.D., Ph.D. Co-Founder

SEAS

Seasonality · DMRA

2020–2026 · monthly returns

Strongest month Nov +17.46%Weakest month Apr −12.81%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	14.0	12.8	-12.4	-0.9	-3.0	4.5	11.5	-2.8	-24.5	-5.5			−12.6%
2025	6.7	-11.7	-29.2	-9.7	9.6	11.1	-3.5	-3.3	17.0	96.8	142.9	29.4	+394.8%
2024	-15.0	17.6	8.3	-13.3	-10.1	-22.0	19.0	-15.2	1.7	-43.6	-22.6	-12.3	−74.2%
2023	100.0	-4.8	-9.1	-11.6	23.9	15.6	22.2	-80.4	19.0	-26.4	18.9	14.3	−37.4%
2022	-20.8	-22.9	18.9	-23.6	-22.0	32.1	-6.9	33.5	-12.1	6.3	-21.9	-26.8	−62.0%
2021	-1.0	-16.1	-41.5	-5.8	-7.2	-4.7	-15.2	3.7	-19.3	-8.1	-14.5	7.4	−75.8%
2020											2.1	-18.3	−16.6%

INSD

Insider Activity · DMRA

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

21.59M shares

Sells, 6 months

1.51M shares

Net shares

+20.08M

Net change in insider shares

−135.00%

Date	Insider	Transaction	Shares	Value
Sep 24, 2026	Jarrett A JenniferChief Executive Officer	Purchase at price 20.23 per share.	12.5K	$252.88K
Jul 5, 2026	Winslow GarrettGeneral Counsel	Sale at price 29.98 per share.	245	$7.34K
Jul 1, 2026	Winslow GarrettGeneral Counsel	—	680	—
Mar 29, 2026	Jarrett A JenniferChief Executive Officer	—	500K	—
Feb 8, 2026	Fairmount Funds Management LlcDirector and Beneficial Owner of more than 10% of a Class of Security	—	8.71M	—
Feb 8, 2026	Bruno JulianneDirector	—	129K	—
Jan 4, 2026	Hewes Lemuel BeckerOfficer	—	264.6K	—
Jan 4, 2026	Sattarzadeh SherwinChief Operating Officer	—	190.4K	—
Jan 1, 2026	Schambye Hans T.Chief Executive Officer	Sale at price 21.38 per share.	700	$14.97K
Jan 1, 2026	Schambye Hans T.Chief Executive Officer	—	1.4K	—
Jan 1, 2026	Winslow GarrettGeneral Counsel	Sale at price 21.38 per share.	255	$5.45K
Jan 1, 2026	Winslow GarrettGeneral Counsel	—	680	—
Jan 1, 2026	Firmani LoriChief Financial Officer	Sale at price 21.41 per share.	135	$2.89K
Jan 1, 2026	Firmani LoriChief Financial Officer	—	374	—
Jul 2, 2025	Schambye Hans T.Chief Executive Officer	Sale at price 3.38 per share.	735	$2.48K
Jul 2, 2025	Schambye Hans T.Chief Executive Officer	—	1.4K	—
Jul 2, 2025	Winslow GarrettGeneral Counsel	Sale at price 3.39 per share.	260	$881
Jul 2, 2025	Winslow GarrettGeneral Counsel	—	680	—
Jul 2, 2025	Firmani LoriChief Financial Officer	Sale at price 3.39 per share.	147	$498
Jul 2, 2025	Firmani LoriChief Financial Officer	—	374	—

13F

Investors Holding DMRA

latest 13F filings of 29 followed managers

Investors holding DMRA
Investor	Value	Of portfolio	Shares	Change	Quarter
Viking Global · Andreas Halvorsen	$60.1M	0.17%	2.31M	—	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

DMRA

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

DMRA

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Damora Therapeutics, Inc.

Seasonality · DMRA

Insider Activity · DMRA

Congress Trades · DMRA

Investors Holding DMRA

Investors Holding DMRA

Congress Trades · DMRA

Insider Activity · DMRA

Seasonality · DMRA

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Damora Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News